文献速递肾癌与肾肿瘤

手术等待时间对病理T1b-2期肾癌肿瘤特异性死亡率的影响

The effect of time to nephrectomy on cancer-specific mortality in pathological T stage (pT)1b-2 renal cancer.
PubMed 文献 · BJU Int · 2026-09-29

倾向性评分匹配及竞争风险回归显示,等待>3个月独立预测CSM升高1.3倍(P=0.02),且呈剂量反应效应;该不良影响在非透明细胞癌中未观察到。

要点

  • pT1b-2N0M0肾癌手术等待>3个月与CSM升高1.3倍独立相关(P=0.02)。
  • 等待3-6个月CSM升高1.3倍,>6个月升高1.6倍,呈剂量反应效应。
  • 该不良影响在各分级中一致,但非透明细胞癌中未观察到。

核心结论

  • 在pT1b-2N0M0接受部分或根治性肾切除术的患者中,从诊断到手术时间延长与更高的CSM相关。
  • 该关联在非透明细胞肾细胞癌患者中未观察到。

研究设计与样本

  • 采用倾向性评分匹配(PSM)和多变量竞争风险回归(CRR),并按手术等待时间区间、组织学类型和分级进行亚组分析。

主要发现

  • 手术等待>3个月者3023例(18%),年龄更大(中位64 vs 62岁),pT2比例更低(19% vs 30%)。
  • 一对一PSM后,等待>3个月者60个月CSM为7.6%,等待≤3个月者为5.9%。
  • CRR中等待>3个月独立预测CSM升高1.3倍(P=0.02)。
  • 亚组分析显示剂量反应效应:等待3-6个月CSM升高1.3倍,>6个月升高1.6倍。
  • 等待>3个月的不良影响在所有分级中一致,但非透明细胞肾细胞癌中未观察到。

关键数值与推荐

  • 手术等待时间>3个月 vs ≤3个月为暴露定义。
  • 亚组按等待区间(≤1 vs 1-3个月、≤3 vs 3-6个月、≤3 vs >6个月)、组织学类型和分级分层。

临床怎么用

  • 对pT1b-2N0M0肾癌应尽量避免诊断至手术时间超过3个月,尤其是透明细胞癌患者。
  • 非透明细胞肾细胞癌患者手术等待时间延长的风险信号较弱,但仍需个体化评估。

局限性

  • 回顾性SEER数据库研究,存在未测量混杂可能。
  • 原文摘要未报告更多局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the impact of prolonged time to surgery on cancer-specific mortality (CSM) in patients with pathological T stage (pT)1b-2 N0M0 renal cell carcinoma (RCC) treated with nephrectomy (either partial [PN] or radical [RN]). Within the Surveillance, Epidemiology and End Results (SEER) database (2004-2021), we tested the effect of time to surgery >3 vs ≤3 months on CSM in patients with pT1b-2N0M0 RCC. PATIENTS AND METHODS: Propensity score matching (PSM) and multivariable competing risks regression (CRR) were performed. Subgroup analyses stratified patients according to time to surgery interval (≤1 vs 1-3 months, ≤3 vs 3-6 months, ≤3 vs >6 months), histotype, and grade. RESULTS: Of 16 322 patients with pT1b-2 RCC treated with nephrectomy, time to surgery >3 months was recorded in 3023 (18%) patients. These patients were older (median age 64 vs 62 years) and harboured a smaller proportion of pT2 patients (19% vs 30%). After one-to-one PSM, 3023 (100%) patients with a time to surgery >3 months exhibited a 60-month CSM of 7.6% vs 5.9% in 3023 (23%) patients with a time to surgery ≤3 months. In CRR time to surgery >3 months independently predicted 1.3-fold higher CSM (P = 0.02). Subgroup analyses revealed a dose-response effect, with a CSM increase in 1.3-fold fashion when time to surgery was 3-6 months vs 1.6-fold fashion when time to surgery was >6 months. The detrimental effect of time to surgery>3 months was consistent across all grades but was not evidenced among patients with a non-clear cell RCC. CONCLUSION: In patients with pT1b-2N0M0 treated with either PN or RN, prolonged time from diagnosis to surgery was associated with higher CSM. This association was not observed among patients with non-clear cell RCC.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Nicolazzini M, Polverino F, Quarta L, et al. The effect of time to nephrectomy on cancer-specific mortality in pathological T stage (pT)1b-2 renal cancer. BJU Int. 2026. PMID: 42808865. doi:10.1111/bju.70468

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。